Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022.
暂无分享,去创建一个
R. Baric | D. Wesemann | A. Griffiths | G. Alter | C. Linde | J. Desjarlais | A. Schäfer | Pei Tong | T. Zuo | J. Goudsmit | C. Mire | S. Leist | S. Fischinger | C. Atyeo | Matthew D. Slein | J. Burke | T. Suscovich | N. Kuzmina | A. Honko | Rebecca I Johnson | A. Bukreyev | N. Storm | M. Bernett | Adam Zuiani | B. Juelg | Jun Lin | J. Burke | Rebecca I. Johnson
[1] Jing Shan,et al. Correction to: 2019 Novel coronavirus: where we are and what we know , 2020, Infection.
[2] T. Musa,et al. Bibliometric Analysis of Ebola Research Indexed in Web of Science and Scopus (2010-2020) , 2020, BioMed research international.
[3] D. Lauffenburger,et al. Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques , 2020, Nature.
[4] Tokiko Watanabe,et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development , 2020, Proceedings of the National Academy of Sciences.
[5] H. Yen,et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters , 2020, Nature.
[6] Victor G. Puelles,et al. Multiorgan and Renal Tropism of SARS-CoV-2 , 2020, The New England journal of medicine.
[7] F. Gao,et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2 , 2020, Science.
[8] Lisa E. Gralinski,et al. A mouse-adapted SARS-CoV-2 model for the evaluation of COVID-19 medical countermeasures , 2020, bioRxiv.
[9] Fabian J Theis,et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes , 2020, Nature Medicine.
[10] Erwan L'Her,et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19 , 2020, The New England journal of medicine.
[11] Chonggang Xu,et al. High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2 , 2020, Emerging infectious diseases.
[12] P. Vollmar,et al. Virological assessment of hospitalized patients with COVID-2019 , 2020, Nature.
[13] S. Ruan. Likelihood of survival of coronavirus disease 2019 , 2020, The Lancet Infectious Diseases.
[14] Fabian J Theis,et al. SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues , 2020, Cell.
[15] Nicholas C. Wu,et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV , 2020, Science.
[16] D. Raoult,et al. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? , 2020, International Journal of Antimicrobial Agents.
[17] Vineet D. Menachery,et al. Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States , 2020, Emerging infectious diseases.
[18] S. Zhang,et al. Estimation of the reproductive number of novel coronavirus (COVID-19) and the probable outbreak size on the Diamond Princess cruise ship: A data-driven analysis , 2020, International Journal of Infectious Diseases.
[19] Richard T. Ellison,et al. Update on COVID-19 , 2020 .
[20] Jing Shan,et al. 2019 Novel coronavirus: where we are and what we know , 2020, Infection.
[21] Jing Zhao,et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.
[22] Kenneth D Mandl,et al. Early Transmissibility Assessment of a Novel Coronavirus in Wuhan, China. , 2020, SSRN.
[23] Zhènglì Shí,et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody , 2020, bioRxiv.
[24] G. Alter,et al. A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation☆ , 2019, Journal of immunological methods.
[25] G. Alter,et al. A versatile high-throughput assay to characterize antibody-mediated neutrophil phagocytosis , 2019, Journal of immunological methods.
[26] Chuan Qin,et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. , 2019, JCI insight.
[27] F. Grosveld,et al. Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein , 2019, Emerging microbes & infections.
[28] Chuan Qin,et al. From SARS to MERS, Thrusting Coronaviruses into the Spotlight , 2019, Viruses.
[29] D. Lauffenburger,et al. A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus. , 2018, Cell host & microbe.
[30] J. Dye,et al. Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection , 2018, Cell.
[31] D. Dimitrov,et al. Human monoclonal antibodies as candidate therapeutics against emerging viruses , 2017, Frontiers of Medicine.
[32] M. Halloran,et al. Antibody-dependent enhancement of severe dengue disease in humans , 2017, Science.
[33] Michael B. Otteneder,et al. Distribution of FcRn Across Species and Tissues , 2017, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[34] Karen G. Dowell,et al. Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles , 2017, Journal of immunological methods.
[35] M. Quigley,et al. Role of Fc–FcγR interactions in the antitumor activity of therapeutic antibodies , 2017, Immunology and cell biology.
[36] Jacky Flipse,et al. How antibodies alter the cell entry pathway of dengue virus particles in macrophages , 2016, Scientific Reports.
[37] D. Falzarano,et al. SARS and MERS: recent insights into emerging coronaviruses , 2016, Nature Reviews Microbiology.
[38] B. Walker,et al. Antigen-Specific Antibody Glycosylation Is Regulated via Vaccination , 2016, PLoS pathogens.
[39] Jerome H. Kim,et al. Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology , 2015, Cell.
[40] R. Bruzzone,et al. Fc receptors in antibody‐dependent enhancement of viral infections , 2015, Immunological reviews.
[41] K. Yuen,et al. A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein , 2015, Cell Research.
[42] R. Baric,et al. Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus , 2015, Proceedings of the National Academy of Sciences.
[43] Jincun Zhao,et al. Passive Immunotherapy with Dromedary Immune Serum in an Experimental Animal Model for Middle East Respiratory Syndrome Coronavirus Infection , 2015, Journal of Virology.
[44] Fu-Tong Liu,et al. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins , 2014, Biochemical and Biophysical Research Communications.
[45] J. Peiris,et al. Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus , 2014, Virology Journal.
[46] R. Kelley,et al. Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys , 2013, mAbs.
[47] C. Bailey-Kellogg,et al. High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples. , 2012, Journal of immunological methods.
[48] P. Parren,et al. Crosstalk between Human IgG Isotypes and Murine Effector Cells , 2012, The Journal of Immunology.
[49] J. Peiris,et al. Anti-Severe Acute Respiratory Syndrome Coronavirus Spike Antibodies Trigger Infection of Human Immune Cells via a pH- and Cysteine Protease-Independent FcγR Pathway , 2011, Journal of Virology.
[50] D. Irvine,et al. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. , 2010, Journal of immunological methods.
[51] S. Qiao,et al. Neonatal Fc Receptor: From Immunity to Therapeutics , 2010, Journal of Clinical Immunology.
[52] G. Lazar,et al. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions , 2010, mAbs.
[53] D. Cleri,et al. Severe Acute Respiratory Syndrome (SARS) , 2010, Infectious Disease Clinics of North America.
[54] Shibo Jiang,et al. The spike protein of SARS-CoV — a target for vaccine and therapeutic development , 2009, Nature Reviews Microbiology.
[55] Jaap Goudsmit,et al. Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants , 2006, PLoS medicine.
[56] G. A. Lazar,et al. Engineered antibody Fc variants with enhanced effector function. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[57] Kwanyee Leung,et al. Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[58] Y. Kawaoka,et al. Antibody‐dependent enhancement of viral infection: molecular mechanisms and in vivo implications , 2003, Reviews in medical virology.
[59] P. Bruhns,et al. FcgammaRIV: a novel FcR with distinct IgG subclass specificity. , 2005, Immunity.